Author Archives: Hank

Watson Pharmaceuticals Incorporated (WPI) Shares Downgraded to “Neutral” by Citigroup (C) Analysts Watson Pharmaceuticals Incorporated (NYSE: WPI) was downgraded by investment analysts at Citigroup (NYSE: C) from a “buy” rating to a “neutral” rating in a note issued to investors … Continue reading →

Cubist Pharmaceuticals (CBST) Posts Quarterly Results Cubist Pharmaceuticals (CBST) posted its quarterly earnings results on Thursday. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of $0.31 by $0.20. The company’s quarterly … Continue reading →

Pharmaceutical M&A in the Asia Pacific Region Slowing growth continues in major developed markets, prompted by generic erosion of branded sales and increasing regulatory and cost containment pressures. Expansion into emerging Asia Pacific (APAC) markets is appealing not only because … Continue reading →

Swiss drug maker Novartis to cut almost 2,000 US jobs this year on patent expiry, failed trial Drug maker Novartis will cut 1,960 jobs in the United States this year in anticipation of lower sales for two of its hypertension … Continue reading →

Bulgaria Pharmaceuticals and Healthcare Report Q1 2012 Business Monitor International’s Bulgaria Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Bulgaria’s pharmaceuticals and healthcare … Continue reading →

Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection Diplomat Specialty Pharmacy, the nation’s largest independent specialty pharmacy in the nation, announced today it has received limited distribution rights from Regeneron for its new drug EYLEA™ (aflibercept) … Continue reading →

Apeiron, GSK begin phase IIa trial in Acute Lung Injury patients Apeiron Biologics announced that GlaxoSmithKline (GSK), that has licensed Apeiron´s new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has commenced a phase IIa study … Continue reading →

Cantor Fitzgerald Analysts Reiterate a “Buy” Rating on Salix Pharmaceuticals (SLXP) Salix Pharmaceuticals (NASDAQ: SLXP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. Separately, analysts at … Continue reading →

Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. IPXL +0.11% , announced that it has initiated a Phase IIb trial of its drug candidate IPX159 in … Continue reading →